HomeNewsGlobal Pharma

Zydus Lifesciences Receives 6 Observations from USFDA for API Site at Changodar

Zydus Lifesciences Receives 6 Observations from USFDA for API Site at Changodar

Zydus Lifesciences Ltd has announced that the USFDA conducted an inspection at the API site situated at Changodar, Ahmedabad. This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023. The inspection closed with 6 observations. There were no Data Integrity related observations. There are no repeat observations from the previous inspection.

There are 4 DMFs of this site under approval with the USFDA. The Company will closely work with the USFDA to address the observations. 

Read more on:
More news about: global pharma | Published by Manvi | December - 26 - 2023 | 629

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members